We are live on ! Find out more
SCM

Suvretta Capital Management Portfolio holdings

AUM $3.92B
1-Year Est. Return 86.67%
This Fund
S&P 500
This Quarter Est. Return
-5.35%
1 Year Est. Return
+86.67%
3 Year Est. Return
+295.96%
5 Year Est. Return
+364.48%
10 Year Est. Return
+2,073.65%
AUM
$2.69B
AUM Growth
-$239M
Cap. Flow
+$33.3M
Cap. Flow %
1.24%
Top 10 Hldgs %
47.52%
Holding
112
New
16
Increased
29
Reduced
14
Closed
12

Top Buys

Rank Stock Value
1
HD icon
Home Depot
HD
+$38M
2
RARE icon
Ultragenyx Pharmaceutical
RARE
+$36.3M
3
ETNB
89bio
ETNB
+$36.1M
4
BAC icon
Bank of America
BAC
+$33.6M
5
CMG icon
Chipotle Mexican Grill
CMG
+$29.3M

Top Sells

Rank Stock Value
1
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$92M
2
KO icon
Coca-Cola
KO
+$48.2M
3
SBUX icon
Starbucks
SBUX
+$47M
4
CRH icon
CRH
CRH
+$41.5M
5
MCD icon
McDonald's
MCD
+$30M

Sector Composition

Rank Sector Weight
1 Healthcare 60.02%
2 Technology 10.47%
3 Consumer Discretionary 6.61%
4 Financials 5.33%
5 Communication Services 4.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RBLX icon
51
Roblox
RBLX
$27B
$13.3M 0.49%
+227,710
New +$14.3M
MRK icon
52
Merck
MRK
$318B
$12.9M 0.48%
144,100
+91,100
+172% +$8.51M
CTNM
53
Contineum Therapeutics
CTNM
$566M
$12M 0.45%
1,720,000
– –
PROK icon
54
ProKidney
PROK
$337M
$10.8M 0.4%
12,341,266
– –
MOLN
55
Molecular Partners
MOLN
$152M
$8.62M 0.32%
2,221,494
– –
ABT icon
56
Abbott
ABT
$187B
$7.8M 0.29%
58,820
+25,300
+75% +$3.22M
GLUE icon
57
Monte Rosa Therapeutics
GLUE
$1.35B
$7.26M 0.27%
1,563,798
– –
U icon
58
Unity
U
$18.9B
$6.65M 0.25%
+339,560
New +$7.67M
IFRX icon
59
InflaRx
IFRX
$271M
$6.61M 0.25%
6,483,910
+750,000
+13% +$1.41M
WHWK
60
Whitehawk Therapeutics
WHWK
$271M
$6.59M 0.24%
+3,700,000
New +$9.66M
ZURA icon
61
Zura Bio
ZURA
$567M
$6.27M 0.23%
4,860,939
– –
BIOA
62
BioAge Labs
BIOA
$538M
$5.46M 0.2%
1,452,336
– –
STRO icon
63
Sutro Biopharma
STRO
$421M
$4.86M 0.18%
746,250
– –
SNY icon
64
Sanofi
SNY
$104B
$4.64M 0.17%
83,701
-47,800
-36% -$2.59M
EXAS
65
DELISTED
Exact Sciences
EXAS
$4.07M 0.15%
94,100
– –
IRON icon
66
Disc Medicine
IRON
$2.97B
$3.97M 0.15%
+80,000
New +$4.45M
TMO icon
67
Thermo Fisher Scientific
TMO
$220B
$3.93M 0.15%
7,900
– –
KZR
68
DELISTED
Kezar Life Sciences
KZR
$3.5M 0.13%
716,759
– –
COR icon
69
Cencora
COR
$61.2B
$3.47M 0.13%
12,488
– –
DHR icon
70
Danaher
DHR
$144B
$2.79M 0.1%
13,600
– –
ELAN icon
71
Elanco Animal Health
ELAN
$11.1B
$2.66M 0.1%
253,600
– –
ISRG icon
72
Intuitive Surgical
ISRG
$134B
$2.58M 0.1%
5,200
– –
ALNY icon
73
Alnylam Pharmaceuticals
ALNY
$29.3B
$2.53M 0.09%
+9,370
New +$2.41M
AARD
74
Aardvark Therapeutics
AARD
$173M
$2.35M 0.09%
+312,500
New +$3.51M
PEPG icon
75
PepGen
PEPG
$197M
$2.33M 0.09%
1,660,932
+486,611
+41% +$1M
1 2
3
4 5

Similar funds

MIM
Meridiem Investment Management London, United Kingdom $3.92B AUM 1.64% 1-Year Est. Return
BCP
BSN Capital Partners London, United Kingdom $3.93B AUM 13.09% 1-Year Est. Return
AS
American Securities New York $3.93B AUM 52.22% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $3.9B AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
LWCA
Locust Wood Capital Advisers New York $3.95B AUM 33.1% 1-Year Est. Return
TFM
Trian Fund Management New York $3.86B AUM 26.59% 1-Year Est. Return
USCWA
U.S. Capital Wealth Advisors Austin, Texas $3.98B AUM 22.36% 1-Year Est. Return

Suvretta Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, Suvretta Capital Management held 112 positions worth $2.69B, down 8.2% from $2.93B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Suvretta Capital Management's Q1 2025 filing shows 16 new, 29 increased, 14 reduced and 12 closed positions. Its largest new stake was Home Depot: 97,571 shares worth $35.8M. The largest sale was Intra-Cellular Therapies Inc., an estimated $92M.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, up from 56% a quarter earlier, followed by Technology and Consumer Discretionary.

  • Suvretta Capital Management's largest Q1 2025 buy was Home Depot: 97,571 shares worth $35.8M.
  • Suvretta Capital Management added most to Ultragenyx Pharmaceutical in Q1 2025, an estimated $36.3M increase.
  • Suvretta Capital Management's biggest Q1 2025 reduction was Intra-Cellular Therapies Inc., cutting an estimated $92M.
  • Suvretta Capital Management fully exited Starbucks in Q1 2025, selling an estimated $47M.
  • Suvretta Capital Management's ten largest holdings make up 48% of its $2.69B portfolio in Q1 2025.
  • Suvretta Capital Management opened 16 new positions and closed 12 in Q1 2025.
  • Suvretta Capital Management's portfolio value fell 8.2% quarter-over-quarter to $2.69B.

Based on Suvretta Capital Management's 13F filing for Q1 2025, filed 15 May 2025.